Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amikacin (Primary)
  • Indications Mycobacterium avium complex infections; Nontuberculous mycobacterium infections; Respiratory tract infections
  • Focus Therapeutic Use
  • Acronyms TARGET-NTM
  • Sponsors Insmed

Most Recent Events

  • 19 May 2021 According to an Insmed media release, data from this trial will be presented at he virtual American Thoracic Society (ATS) 2021 International Conference.
  • 17 Feb 2021 Results (n=53) of pooled analysis of TR02-112 and CONVERT trials, assessing the pharmacokinetic properties of once-daily amikacin liposome inhalation suspension in patients with treatment-refractory NTM lung disease, published in the European Journal of Drug Metabolism and Pharmacokinetics
  • 01 Apr 2019 According to an Insmed media release, results of pooled pharmacokinetic analysis from this and a phase III study (CONVERT) will be presented at the American Thoracic Society (ATS) International Conference in May 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top